Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: The FinnDiane Study

Journal of Internal Medicine

Volumn 273, Issue 4, 2013, Pages 383-395

  Makinen V P ^a,b,c,d,e   Soininen, P ^a,f   Kangas, A J ^a   Forsblom, C ^c,d   Tolonen, N ^c,d   Thorn, L M ^c,d   Viikari, J ^g   Raitakari, O T ^g,h   Savolainen, M ^a,b   Groop, P H ^d,e,i   Ala Korpela, M ^a,b,e,j  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e CENTRAL SOUTH UNIVERSITY   (China)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h UNIVERSITY OF TURKU   (Finland)

ⁱ BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Lipoprotein subclasses; Nephropathy; Proton NMR; Triglycerides; Type 1 diabetes

Indexed keywords

APOLIPOPROTEIN B; HEMOGLOBIN A1C; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; DISEASE DURATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; FINLAND; HUMANS; INCIDENCE; LIPOPROTEINS; MALE; PROGNOSIS; SURVIVAL RATE; TRIGLYCERIDES;

EID: 84875521707     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12026     Document Type: Article

References (52)

1. Nikkilä E, Hormila P. Serum lipids and lipoproteins in insulin-treated diabetes. demonstration of increased high density lipoprotein concentrations. Diabetes 1978; 27: 1078-86.
2. The DCCT Writing Team. Lipid and lipoprotein levels in patients with IDDM. Diabetes Care 1992; 15: 886-94.
3. Groop P-H, Thomas MC, Rosengård-Bärlund M et al. HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes. Diabetes Care 2007; 30: 2706-7.
4. Thomas MC, Rosengård-Bärlund M, Mills V et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 2006; 29: 317-22.
5. Vergès B. Lipid disorders in type 1 diabetes. Diabetes Metab 2009; 35: 353-60.
6. Jenkins AJ, Lyons TJ, Zheng D et al. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 2003; 64: 817-28.
7. Jenkins AJ, Lyons TJ, Zheng D et al. Serum lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort: associations with gender and glycemia. Diabetes Care 2003; 26: 810-18.
8. Soedamah-Muthu SS, Chang Y, Otvos J, Evans RW, Orchard TJ. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in type 1 diabetes. a prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2003; 46: 674-82.
9. Mäkinen V-P, Forsblom C, Thorn LM et al. Metabolic phenotypes, vascular complications, and premature deaths in a population of 4, 197 patients with type 1 diabetes. Diabetes 2008; 57: 2480-7.
10. Bagdade JD, Subbaiah PV. Abnormal high-density lipoprotein composition in women with insulin-dependent diabetes. J Lab Clin Med 1989; 113: 235-40.
11. Al-Shahrouri HZ, Ramirez P, Fanti P, Abboud H, Lorenzo C, Haffner S. NMR identifies atherogenic lipoprotein abnormalities in early diabetic nephropathy that are unrecognized by conventional analysis. Clin Nephrol 2010; 73: 180-9.
12. Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127-35.
13. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol 2009; 24: 345-50.
14. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009; 119: 931-9.
15. Kapur NK, Ashen D, Blumenthal RS. High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. Vasc Health Risk Manag 2008; 4: 39-57.
16. Kastelein JJP, van der Steeg WA, Holme I et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117: 3002-9.
17. Okazaki M, Usui S, Ishigami M et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol 2005; 25: 578-84.
18. 1H NMR metabonomics of serum. Magn Reson Mater Phys 2006; 19: 281-96.
19. Inouye M, Kettunen J, Soininen P et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol 2010; 6: 441.
20. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol 2008; 4: 167.
21. Mäkinen V-P, Tynkkynen T, Soininen P et al. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes. J Proteome Res 2012; 11: 1782-90.
22. Raiko JRH, Viikari JSA, Ilmanen A et al. Follow-ups of the Cardiovascular Risk in Young Finns Study in 2001 and 2007: levels and 6-year changes in risk factors. J Intern Med 2010; 267: 370-84.
23. Vaziri ND. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial 2009; 22: 644-51.
24. Attman P, Samuelsson O, Alaupovic P. The effect of decreasing renal function on lipoprotein profiles. Nephrol Dial Transplant 2011; 26: 2572-5.
25. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol 2009; 5: 713-21.
26. Warwick GL, Packard CJ, Demant T, Bedford DK, Boulton-Jones JM, Shepherd J. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 1991; 40: 129-38.
27. The EDIC Writing Team. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications Study. JAMA 2003; 290: 2159-67.
28. Raile K, Galler A, Hofer S et al. Diabetic nephropathy in 27, 805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1c, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 2007; 30: 2523-8.
29. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 1988; 33: 917-24.
30. Peric-Golia L, Peric-Golia M. Aortic and renal lesions in hypercholesterolemic adult, male, virgin Sprague-Dawley rats. Atherosclerosis 1983; 46: 57-65.
31. Keane WF, Kasiske BL, O'Donnell MP, Kim Y. The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 1991; 17: 38-42.
32. Gröne HJ, Walli AK, Gröne EF. Arterial hypertension and hyperlipidemia as determinants of glomerulosclerosis. Clin Investig 1993; 71: 834-9.
33. Boini KM, Zhang C, Xia M, Poklis JL, Li P. Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther 2010; 334: 839-46.
34. Yang G, Badeanlou L, Bielawski J, Roberts AJ, Hannun YA, Samad F. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009; 297: E211-24.
35. Mäkinen VP, Tynkkynen T, Soininen P et al. Sphingomyelin is associated with kidney disease in type 1 diabetes. Metabolomics 2012; 8: 369-75.
36. Fornoni A, Sageshima J, Wei C et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3: 85ra46.
37. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 2001; 60: 219-27.
38. Tolonen N, Forsblom C, Thorn L et al. Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia 2009; 52: 2522-30.
39. de Boer IH, Rue TC, Cleary PA et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort. Arch Intern Med 2011; 171: 412-20.
40. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17: 2006-16.
41. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-24.
42. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006; 26: 847-70.
43. 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics. Clin Chem Lab Med 2008; 46: 27-42.
44. Soininen P, Kangas AJ, Würtz P et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009; 134: 1781-5.
45. Tukiainen T, Kettunen J, Kangas AJ et al. Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Hum Mol Genet 2012; 21: 1444-55.
46. Murphy AJ, Chin-Dusting JPF, Sviridov D, Woollard KJ. The anti-inflammatory effects of high density lipoproteins. Curr Med Chem 2009; 16: 667-75.
47. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010; 21: 229-38.
48. Andrews KL, Moore XL, Chin-Dusting JPF. Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium. Clin Exp Pharmacol Physiol 2010; 37: 736-42.
49. Sandhofer A, Kaser S, Ritsch A et al. Cholesteryl ester transfer protein in metabolic syndrome. Obesity 2006; 14: 812-18.
50. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010; 31: 149-64.
51. Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr 2009; 19: 73-7.
52. Kettunen J, Tukiainen T, Sarin A et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012; 44: 269-76.